PARP Inhibitor Therapy for Neurodegeneration

Overview

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes involved in DNA repair, cellular stress responses, and cell death pathways. In neurodegenerative diseases, overactivation of PARP (particularly PARP1) leads to excessive NAD+ depletion, energy failure, and programmed cell death. PARP inhibitors, originally developed for cancer, represent a repurposing opportunity for neuroprotection by preventing NAD+ exhaustion and promoting DNA repair in [neurons](/entities/neurons) and glia.

Mechanism of Action

Pathological Context

Overview

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes involved in DNA repair, cellular stress responses, and cell death pathways. In neurodegenerative diseases, overactivation of PARP (particularly PARP1) leads to excessive NAD+ depletion, energy failure, and programmed cell death. PARP inhibitors, originally developed for cancer, represent a repurposing opportunity for neuroprotection by preventing NAD+ exhaustion and promoting DNA repair in [neurons](/entities/neurons) and glia.

Mechanism of Action

Pathological Context

PARP1 is rapidly activated by DNA strand breaks that accumulate in neurons due to oxidative stress, mitochondrial dysfunction, and aging[@berger1985]. While PARP-mediated DNA repair is essential, overactivation leads to:

• NAD+ depletion: PARP consumes NAD+ to synthesize poly(ADP-ribose), depleting cellular energy stores
• ATP exhaustion: NAD+ depletion triggers ATP consumption in a futile cycle attempting to restore NAD+
• AIF translocation: Severe PARP activation triggers [apoptosis](/entities/apoptosis)-inducing factor (AIF) translocation to nucleus
• Neuroinflammation: PARP activation in glial cells promotes inflammatory responses

Therapeutic Strategy

Primary Mechanism: PARP inhibitors (particularly PARP1-selective) prevent excessive PARP activation, preserving NAD+ and ATP levels during DNA damage stress[@moroni2008].

Secondary Mechanism: By maintaining NAD+ pools, PARP inhibitors support sirtuin (SIRT1) activity, promoting cellular stress resistance and mitochondrial function.

Tertiary Mechanism: Some PARP inhibitors also enhance DNA repair fidelity, potentially preventing the accumulation of deleterious mutations in neurons.

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 6 | Established drug class (cancer); repurposing for neurodegeneration is emerging |
| Mechanistic Rationale | 8 | Strong preclinical data; addresses energy crisis and DNA repair |
| Addresses Root Cause | 7 | Targets oxidative stress response and energy failure; complementary to other approaches |
| Delivery Feasibility | 7 | Many PARP inhibitors have good oral bioavailability; some CNS penetration demonstrated |
| Safety Plausibility | 7 | Well-characterized safety profile from oncology; hematological effects need monitoring |
| Combinability | 8 | Synergistic with NAD+ precursors, sirtuin activators, and mitochondrial protectants |
| Biomarker Availability | 7 | NAD+ levels, DNA damage markers, PAR levels can be measured |
| De-risking Path | 8 | Multiple PARP inhibitors already approved; clear regulatory path |
| Multi-disease Potential | 8 | Strong rationale for AD, PD, ALS, stroke, and traumatic brain injury |
| Patient Impact | 7 | Addresses fundamental cellular energetics; broad applicability |

Total Score: 72/100

Preclinical Evidence

PARP Inhibition Models

• Stroke models: PARP inhibitors significantly reduce infarct size and improve functional outcomes in rodent stroke models[@endres1997]
• PD models: Protect dopaminergic neurons in MPTP and 6-OHDA models[@chiu2008]
• AD models: Reduce DNA damage, improve cognition in [APP](/entities/app-protein)/PS1 mice[@strosznajder2012]
• ALS models: Delay disease progression in SOD1 mice

Key Mechanisms

• NAD+ preservation: PARP inhibitors prevent the dramatic NAD+ depletion seen in neurodegeneration
• Mitochondrial protection: Maintain mitochondrial function and ATP production
• Anti-apoptotic: Prevent AIF-mediated cell death pathway
• Anti-inflammatory: Reduce microglial activation and neuroinflammation

Clinical Data

• Olaparib: Approved for multiple cancers; extensive safety data available
• Niraparib, rucaparib, talazoparib: Additional approved agents with varying CNS penetration

Clinical Development Status

Ongoing Trials

• Phase 2 in ALS: Multiple PARP inhibitors in early clinical testing
• Phase 2 in PD: Evaluating neuroprotective effects
• Preclinical: New PARP1-selective inhibitors with optimized CNS penetration

Repurposing Opportunities

• Olaparib: Good safety profile; potential for repositioning
• Niraparib: Strong preclinical data in neurodegeneration models
• Novel PARP1-selective: In development for CNS indications

Development Pathway

Phase 2 Repurposing (Months 1-18)

• Identify PARP inhibitor with optimal CNS penetration
• Conduct Phase 2 in early AD or PD patients
• Establish biomarker endpoints (NAD+, DNA damage markers)
• Go/No-Go: Demonstrate target engagement and safety

Phase 3 Development (Months 18-36)

• Registrational trial design based on Phase 2
• Accelerated approval pathway using biomarker endpoints
• Potential for orphan drug designation in ALS

Implementation Roadmap

| Phase | Timeline | Cost | Key Milestones |
|-------|----------|------|----------------|
| Phase 2 repurposing | 18 months | $15-25M | Safety, biomarker validation |
| Phase 3 | 18 months | $40-60M | Registrational trial |
| Total | 36 months | $55-85M | |

Academic Centers

• Harvard Medical School (DNA repair, Dr. David Sinclair)
• University of Pittsburgh (PARP biology, Dr. Valerian Kagan)
• Stanford University (Neuroprotection, Dr. Marion Buckwalter)
• University of Texas Southwestern (Mitochondrial medicine, Dr. Elizabeth McCarty)

Company Partnership Opportunities

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnerships

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References